NCT06021418 is a NA clinical trial of DKB-119 in Crow's Feet, sponsored by Dongkook Pharmaceutical Co., Ltd..

Who is sponsoring NCT06021418?

NCT06021418 is sponsored by Dongkook Pharmaceutical Co., Ltd..

What drugs are being tested in NCT06021418?

Interventions in NCT06021418: DKB-119.

What condition does NCT06021418 study?

NCT06021418 studies Crow's Feet.

Is NCT06021418 still recruiting?

NCT06021418 is currently status unknown. Last updated 13 September 2023.

Last reviewed 2023-09-13 · How we verify

NCT06021418

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of DKB-119 in Patients in Crow's Feet

Status unknown NA Last updated 13 September 2023

What this trial tests

NA trial testing DKB-119 in Crow's Feet in 100 participants. Status unknown.

Timeline

2 November 2020

Primary endpoint
8 September 2023

31 October 2023

Quick facts

Lead sponsor	Dongkook Pharmaceutical Co., Ltd.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	100
Start date	2 November 2020
Primary completion	8 September 2023
Estimated completion	31 October 2023
Sites	1 location across South Korea

Drugs / interventions tested

DKB-119

Conditions studied

Crow's Feet — all drugs for Crow's Feet →

Sponsor

Dongkook Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 19 to 70, any sex, with Crow's Feet. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To prove the non-inferiority of DKB-119 by evaluating the injecting efficacy and safety DKB-119 and control for patients in crow's feet

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Crow's Feet

Currently open trials in the same condition.

NCT04818203 — A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on · Phase 1, PHASE2 · recruiting

Other Dongkook Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT06490328 — Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer · Phase 3 · recruiting
NCT04947631 — Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia · Phase 3 · completed
NCT05612958 — Efficacy and Safety of a 'Graft/Prosthesis, Biomaterial (DKM410)' in the Treatment of Both Nasolabial Folds · NA · completed
NCT06021444 — Efficacy and Safety of DKM420 in Patients With Osteoarthritis of Knee · NA · completed
NCT05749380 — Pharmacokinetics and Safety of AmBisome and DKF-5122 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06021418 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dongkook Pharmaceutical Co., Ltd.
Last refreshed: 13 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06021418.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing